Table 4.
Comparison between the different parameters in group B before and after 6 months of treatment (n = 40)
| Before treatment | After 6 months of treatment | Test of sig. | p | ||
|---|---|---|---|---|---|
| AST (IU/ml) | |||||
| Min.-Max. | 69-150 | 10-25 | t = 23.02* | < 0.001* | |
| Mean ±SD | 95 ±21 | 15.6 ±4 | |||
| ALT (IU/ml) | |||||
| Min.-Max. | 88-220 | 11-30 | t = 19.797* | < 0.001* | |
| Mean ±SD | 135.5 ±37.9 | 19.5 ±6.4 | |||
| HBV DNA (IU/ml) | |||||
| Negative | 0 (0%) | 35 (87.5%) | χ2 = 62.222* | McNp < 0.001* | |
| Positive | 40 (100%) | 5 (12.5%) | |||
| FIB-4 | |||||
| Min.-Max. | 0.4-1.8 | 0.2-1.0 | Z = 5.512* | < 0.001* | |
| Median (IQR) | 0.8 (0.6-1.1) | 0.3 (0.3-0.4) | |||
| APRI | |||||
| Min.-Max. | 0.5-1.0 | 0.1-0.3 | Z = 5.512* | < 0.001* | |
| Median (IQR) | 0.6 (0.6-0.8) | 0.1 (0.1-0.1) | |||
χ2 – chi square test, McN – McNemar test, t – paired t-test, Z – Wilcoxon signed ranks test, p – p value for comparing between the studied periods, *statistically significant at p ≤ 0.05